Status:
COMPLETED
Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis
Lead Sponsor:
Sun Yat-sen University
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
Transcatheter arterial chemoembolization (TACE) had been proved to improve the survivals for middle stage hepatocellular carcinoma (HCC), but for advanced stage HCC its' efficacy had not been proved. ...
Eligibility Criteria
Inclusion
- The diagnosis of HCC was based on the diagnostic criteria for HCC used by the European Association for the Study of the Liver (EASL)
- Tumor size \>7 cm with a portal vein invasion, and the tumor was considered to be unresectable
- No previous HCC directed treatment
- Eastern Co-operative Group performance status 0-1
- Liver function: Child's A
Exclusion
- Avascular tumor
- Evidence of hepatic decompensation including ascites, gastrointestinal bleeding or hepatic encephalopathy
- underlying serve cardiac or renal diseases
- Known or suspected allergy to the investigational agent or any agent given in association with this trial
- Diffuse-type HCC
- For patients with main portal vein occlusion, no adequate collateral circulation around the occluded portal vein
Key Trial Info
Start Date :
July 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2010
Estimated Enrollment :
164 Patients enrolled
Trial Details
Trial ID
NCT00646100
Start Date
July 1 2007
End Date
February 1 2010
Last Update
June 6 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cancer Canter Sun Yat-Sen University
Guangzhou, Guangdong, China, 510060